ReviewInternational journal of chronic obstructive pulmonary disease2009
Markers of early disease and prognosis in COPD.
Review in International journal of chronic obstructive pulmonary disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 60 citations in OpenAlex.
- Biomarkers of particulate matter exposure in patients with chronic obstructive pulmonary disease: a systematic review.Journal of thoracic disease · 2023Review
- Twenty years of changes in the definition of early chronic obstructive pulmonary disease.Chinese medical journal pulmonary and critical care medicine · 2023Review
- MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19.Immunobiology · 2021Article
- Heterozygous Alpha-1 Antitrypsin Deficiency Causing Pulmonary Emboli and Pulmonary Bullae.Cureus · 2021Article
- MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19.Genetics and molecular biology · 2021Article
- Animal models of emphysema.Chinese medical journal · 2019Review
- The systemic nature of mustard lung: Comparison with COPD patients.Interdisciplinary toxicology · 2017Review
- Future impact of various interventions on the burden of COPD in Canada: a dynamic population model.PloS one · 2012Article
- Proteostasis: a new therapeutic paradigm for pulmonary disease.Proceedings of the American Thoracic Society · 2011Article
- CFTR expression regulation by the unfolded protein response.Methods in enzymology · 2011Article
- Early COPD: current evidence for diagnosis and management.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COPD is a complex disease with multiple pathological components, which we unfortunately tend to ignore when spirometry is used as the only method to evaluate the disorder. Additional measures are needed to allow a more complete and clinically relevant assessment of COPD. The earliest potential risk factors of disease in COPD are variations in the genetic background. Genetic variations are present from conception and can determine lifelong changes in enzyme activities and protein concentrations. In contrast, measurements in blood, sputum, exhaled breath, broncho-alveolar lavage, and lung biopsies may vary substantially over time. This review explores potential markers of early disease and prognosis in COPD by examining genetic markers in the alpha(1)-antitrypsin, cystic fibrosis transmembrane conductance regulator (CFTR), and MBL-2 genes, and by examining the biochemical markers fibrinogen and C-reactive protein (CRP), which correlate with degree of pulmonary inflammation during stable conditions of COPD. Chronic lung inflammation appears to contribute to the pathogenesis of COPD, and markers of this process have promising predictive value in COPD. To implement markers for COPD in clinical practice, besides those already established for the alpha(1)-antitrypsin gene, further research and validation studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.